Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis

P. Qu; H. Chu; J. G. Ibrahim; J. Peacock; X. J. Shen; J. Tepper; R. S. Sandler; T. O. Keku

doi:10.1038/sj.bjc.6604792

Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis

P. Qu, H. Chu, J. G. Ibrahim, J. Peacock, X. J. Shen, J. Tepper, R. S. Sandler, T. O. Keku

Biostatistics

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The evaluation of tumour molecular markers may be beneficial in prognosis and predictive in therapy. We develop a stopping rule approach to assist in the efficient utilisation of resources and samples involved in such evaluations. This approach has application in determining whether a specific molecular marker has sufficient variability to yield meaningful results after the evaluation of molecular markers in the first n patients in a study of sample size N (n≤N). We evaluated colorectal tumours for mutations (microsatellite instability, K-ras, B-raf, PI3 kinase, and TGFβR-II) by PCR and protein markers (Bcl2, cyclin D1, E-cadherin, hMLH1, ki67, MDM2, and P53) by immunohistochemistry. Using this method, we identified and abandoned potentially uninformative molecular markers in favour of more promising candidates. This approach conserves tissue resources, time, and money, and may be applicable to other studies.

Original language	English (US)
Pages (from-to)	2001-2005
Number of pages	5
Journal	British Journal of Cancer
Volume	99
Issue number	12
DOIs	https://doi.org/10.1038/sj.bjc.6604792
State	Published - Dec 16 2008

Bibliographical note

Funding Information:
This research was supported, in part, by grants from the National Institutes of Health (U01 CA93326 and P50 CA106991).

Funding Information:
We are conducting a population-based study of colorectal cancer in 33 county areas of North Carolina. This study, Cancer Care Outcomes and Surveillance (CanCORS), is a multicentre population-based study, funded by the National Cancer Institute, to evaluate patient, physician. and treatment factors that influence colorectal cancer outcomes. As part of the CanCORS study at the University of North Carolina, we collected tumour tissue on consenting subjects, and constructed tissue microarrays (Kononen et al, 1998) to be used for immunohistochemistry and mutational analysis as part of the UNC GI Specialized Programme in Research Excellence (SPORE) grant. We enrolled 1000 patients (N = 1000) into the study, and the study was approved by the Institutional review board (IRB) of the UNC School of Medicine. From more than 100 patients, we evaluated genetic mutations in p53 (Angelopoulou and Diamandis, 1998; Curtin et al, 2004), K-ras,

Keywords

Efficiency
Molecular markers
Stopping rule
Survival
Variability

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1038/sj.bjc.6604792

Find It

Find It at U of M Libraries

Cite this

@article{01f9929de0b6479b8f92d7f2333ea8a8,

title = "Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis",

abstract = "The evaluation of tumour molecular markers may be beneficial in prognosis and predictive in therapy. We develop a stopping rule approach to assist in the efficient utilisation of resources and samples involved in such evaluations. This approach has application in determining whether a specific molecular marker has sufficient variability to yield meaningful results after the evaluation of molecular markers in the first n patients in a study of sample size N (n≤N). We evaluated colorectal tumours for mutations (microsatellite instability, K-ras, B-raf, PI3 kinase, and TGFβR-II) by PCR and protein markers (Bcl2, cyclin D1, E-cadherin, hMLH1, ki67, MDM2, and P53) by immunohistochemistry. Using this method, we identified and abandoned potentially uninformative molecular markers in favour of more promising candidates. This approach conserves tissue resources, time, and money, and may be applicable to other studies.",

keywords = "Efficiency, Molecular markers, Stopping rule, Survival, Variability",

author = "P. Qu and H. Chu and Ibrahim, {J. G.} and J. Peacock and Shen, {X. J.} and J. Tepper and Sandler, {R. S.} and Keku, {T. O.}",

note = "Funding Information: This research was supported, in part, by grants from the National Institutes of Health (U01 CA93326 and P50 CA106991). Funding Information: We are conducting a population-based study of colorectal cancer in 33 county areas of North Carolina. This study, Cancer Care Outcomes and Surveillance (CanCORS), is a multicentre population-based study, funded by the National Cancer Institute, to evaluate patient, physician. and treatment factors that influence colorectal cancer outcomes. As part of the CanCORS study at the University of North Carolina, we collected tumour tissue on consenting subjects, and constructed tissue microarrays (Kononen et al, 1998) to be used for immunohistochemistry and mutational analysis as part of the UNC GI Specialized Programme in Research Excellence (SPORE) grant. We enrolled 1000 patients (N = 1000) into the study, and the study was approved by the Institutional review board (IRB) of the UNC School of Medicine. From more than 100 patients, we evaluated genetic mutations in p53 (Angelopoulou and Diamandis, 1998; Curtin et al, 2004), K-ras,",

year = "2008",

month = dec,

day = "16",

doi = "10.1038/sj.bjc.6604792",

language = "English (US)",

volume = "99",

pages = "2001--2005",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis

AU - Qu, P.

AU - Chu, H.

AU - Ibrahim, J. G.

AU - Peacock, J.

AU - Shen, X. J.

AU - Tepper, J.

AU - Sandler, R. S.

AU - Keku, T. O.

N1 - Funding Information: This research was supported, in part, by grants from the National Institutes of Health (U01 CA93326 and P50 CA106991). Funding Information: We are conducting a population-based study of colorectal cancer in 33 county areas of North Carolina. This study, Cancer Care Outcomes and Surveillance (CanCORS), is a multicentre population-based study, funded by the National Cancer Institute, to evaluate patient, physician. and treatment factors that influence colorectal cancer outcomes. As part of the CanCORS study at the University of North Carolina, we collected tumour tissue on consenting subjects, and constructed tissue microarrays (Kononen et al, 1998) to be used for immunohistochemistry and mutational analysis as part of the UNC GI Specialized Programme in Research Excellence (SPORE) grant. We enrolled 1000 patients (N = 1000) into the study, and the study was approved by the Institutional review board (IRB) of the UNC School of Medicine. From more than 100 patients, we evaluated genetic mutations in p53 (Angelopoulou and Diamandis, 1998; Curtin et al, 2004), K-ras,

PY - 2008/12/16

Y1 - 2008/12/16

N2 - The evaluation of tumour molecular markers may be beneficial in prognosis and predictive in therapy. We develop a stopping rule approach to assist in the efficient utilisation of resources and samples involved in such evaluations. This approach has application in determining whether a specific molecular marker has sufficient variability to yield meaningful results after the evaluation of molecular markers in the first n patients in a study of sample size N (n≤N). We evaluated colorectal tumours for mutations (microsatellite instability, K-ras, B-raf, PI3 kinase, and TGFβR-II) by PCR and protein markers (Bcl2, cyclin D1, E-cadherin, hMLH1, ki67, MDM2, and P53) by immunohistochemistry. Using this method, we identified and abandoned potentially uninformative molecular markers in favour of more promising candidates. This approach conserves tissue resources, time, and money, and may be applicable to other studies.

AB - The evaluation of tumour molecular markers may be beneficial in prognosis and predictive in therapy. We develop a stopping rule approach to assist in the efficient utilisation of resources and samples involved in such evaluations. This approach has application in determining whether a specific molecular marker has sufficient variability to yield meaningful results after the evaluation of molecular markers in the first n patients in a study of sample size N (n≤N). We evaluated colorectal tumours for mutations (microsatellite instability, K-ras, B-raf, PI3 kinase, and TGFβR-II) by PCR and protein markers (Bcl2, cyclin D1, E-cadherin, hMLH1, ki67, MDM2, and P53) by immunohistochemistry. Using this method, we identified and abandoned potentially uninformative molecular markers in favour of more promising candidates. This approach conserves tissue resources, time, and money, and may be applicable to other studies.

KW - Efficiency

KW - Molecular markers

KW - Stopping rule

KW - Survival

KW - Variability

UR - http://www.scopus.com/inward/record.url?scp=57449113575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57449113575&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604792

DO - 10.1038/sj.bjc.6604792

M3 - Article

C2 - 19018265

AN - SCOPUS:57449113575

SN - 0007-0920

VL - 99

SP - 2001

EP - 2005

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 12

ER -

Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this